Caxton Associates (New York)’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,697
| Closed | -$336K | – | 578 |
|
|
2024
Q1 | $336K | Sell |
1,697
-12,155
| -88% | -$2.41M | 0.02% | 365 |
|
|
2023
Q4 | $2.38M | Sell |
13,852
-1,112
| -7% | -$191K | 0.12% | 103 |
|
|
2023
Q3 | $2.21M | Buy |
14,964
+6,877
| +85% | +$1.02M | 0.3% | 57 |
|
|
2023
Q2 | $1.77M | Buy |
8,087
+2,829
| +54% | +$618K | 0.26% | 79 |
|
|
2023
Q1 | $1.15M | Buy |
5,258
+2,018
| +62% | +$442K | 0.17% | 116 |
|
|
2022
Q4 | $674K | Buy |
+3,240
| New | +$674K | 0.05% | 170 |
|
|
2022
Q2 | – | Sell |
-1,507
| Closed | -$365K | – | 694 |
|
|
2022
Q1 | $365K | Sell |
1,507
-1,050
| -41% | -$254K | 0.03% | 299 |
|
|
2021
Q4 | $666K | Buy |
2,557
+1,084
| +74% | +$282K | 0.07% | 181 |
|
|
2021
Q3 | $388K | Sell |
1,473
-724
| -33% | -$191K | 0.04% | 246 |
|
|
2021
Q2 | $542K | Buy |
+2,197
| New | +$542K | 0.06% | 137 |
|
|
2020
Q4 | – | Sell |
-2,117
| Closed | -$363K | – | 273 |
|
|
2020
Q3 | $363K | Sell |
2,117
-479
| -18% | -$82.1K | 0.04% | 152 |
|
|
2020
Q2 | $498K | Sell |
2,596
-3,865
| -60% | -$741K | 0.04% | 125 |
|
|
2020
Q1 | $952K | Buy |
+6,461
| New | +$952K | 0.18% | 65 |
|
|
2019
Q4 | – | Sell |
-4,248
| Closed | -$574K | – | 520 |
|
|
2019
Q3 | $574K | Buy |
+4,248
| New | +$574K | 0.11% | 105 |
|
|
2018
Q4 | – | Sell |
-2,934
| Closed | -$338K | – | 414 |
|
|
2018
Q3 | $338K | Buy |
+2,934
| New | +$338K | 0.02% | 259 |
|
|
2017
Q2 | – | Sell |
-6,800
| Closed | -$489K | – | 497 |
|
|
2017
Q1 | $489K | Buy |
+6,800
| New | +$489K | ﹤0.01% | 203 |
|